))
S2E04: Alex Harding - Biotech Investing, Entrepreneurship and Drug Pricing
Manage episode 313065883 series 3257692
Content provided by Sharif Vakili. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sharif Vakili or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Is it possible for market competition to lower drug prices in pharma, or are we resigned to ever-increasing prices with each new biotech innovation? Dr. Alex Harding, biotech venture capitalist at Atlas Ventures, VP of Business Development and Corporate Strategy at Remix Therapeutics and MGH internal medicine physician, joins for a multifaceted conversation around drug pricing, being a practicing physician in biotech VC, and life sciences entrepreneurship. A contributor to the biotech newsletter the Timmerman Report, Alex discusses his recent report on the disruptive drug discovery startup, EQRx, that is contending to radically lower drug prices. Join for a thought-provoking conversation around the consequences of EQRx’s business model and the challenges with market-based drug pricing reform in the United States.
This episode marks the end of the summer interseason. The Doctor is Out will be back in a few months after a short break.
36 episodes
Share
